A B S T R A C T The effect of estrogen on prolactin (PRL) release and gonadotropin suppression was assessed in six experiments performed on four hypogonadal women. Ethinyl estradiol at a dose of 1 Ag/kg per day induced a significant elevation of serum PRL levels within the 1st wk of treatment. There was a further rise until a plateau was reached in about 3-4 wk to levels of more than 3 times the initial concentration. This was accompanied by a pattern of increased episodic fluctuation. The corresponding serum luteinizing hormone and follicle-stimulating hormone fell progressively during the study period. These data indicate that a positive feedback relationship between estrogen and PRL release exists in humans.
INTRODUCTION
Evidence that estrogen promotes pituitary prolactin (PRL)' secretion is afforded by the finding of an increased pituitary PRL content and serum PRL concentrations following exogenous estrogen treatment in rats (1) (2) (3) . This positive feedback relationship was maintained even when a large dose of estradiol benzoate was used (500 Ag/day X 6 days) (2, 3) . In humans, clear evidence for the ability of estrogen to induce PRL release has not been reported. Frantz (4) . The availability of a homologous radioimmunoassay for human PRL with necessary specificity and sensitivity for the measurement of circulating PRL (5, 6) has permitted the present investigation, designed to ascertain the relationship between estrogens and PRL release in ovariectomized and post-menopausal human subjects. In addition, the time-course of estrogen treatment on PRL release and gonadotropin inhibition was assessed.
METHODS
Two postmenopausal women and two ovariectomized subjects volunteered for this study (Table I) . They were not taking estrogen or any kind of medication for at least 6 mo before the study. The subjects reported to the ambulatory clinical research facility and were placed at bedrest in a quiet room. A no. 18 Medicut was placed in an antecubital vein and kept open with a slow drip of normal saline. They were awake throughout the test period. Blood samples were obtained at 15-mmn intervals for a period of 3 h before and at weekly intervals during ethinyl estradiol (EE) treatment at a pharmacological dose of 1 jg/kg per day for 4 wk. A total of six experiments were performed. Three studies were initiated at 0800 h (Exps. 1-3), and three studies were begun at 1700 h (Exps. [4] [5] [6] . Repeated studies were performed at 6-8 wk apart between EE treatments (Table I) .
Serum concentration of PRL, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) were determined by radioimmunoassays (5) (6) (7) (8) . A sensitive homologous radioimmunoassay system for PRL similar to that described by Sinha, Selby, Lewis, and VanderLaan was employed for this study (5) . The detailed characterization of this assay in our laboratory has been reported recently (6) . The highly purified human pituitary PRL (Lewis hPRL 201-174) was labelled with 12I. Rabbit anti-hPRL antiserum and highly purified human pituitary PRL (Lewis 203-1) were used as first antibody and standard, respectively. The coefficient of variation was 14.4%o for interassay error and 8.6 for the intraassay error. Using 50 or 100 ,d of serum the minimal detectable level in this assay was 4.0 ng/ml. All samples from a serial study were measured in a single
The Journal of Clinical Investigation Volume 53 February 1974 652-655 (Fig. 1) . The enhanced PRL secretion during EE treatment appears to be prompt (within the 1st wk). There was a continuous rise until a plateau was reached in about 3-4 wk to levels of more than 300% the initial concentration (Table I and Fig. 2 ). The corresponding course for serum LH and FSH (transverse mean+SE) determined in the same aliquots of sera revealed an opposite pattern. The elevated LH (55.0±14.4 mIU/ml) and FSH (89.0±9.2 mIU/ml) levels found during the control studies confirm the hypogonadal state in these subjects (9) . With the dose of EE used, the expected negative feedback effect on gonadotropin secretion required 4 weeks to decline from the postmenopausal levels to the range found in premenopausal women (LH = 11.7=1.9 mIU/ml, FSH = 18.6±4.4 mIU/ml). In terms of relative change, a greater decline of FSH than LH, especially during the 1st wk of EE treatment, was observed (Fig. 2) .
DISCUSSION
The data presented here demonstrate that chronic administration of relatively small amounts of EE to postmenopausal and ovariectomized women induced an augmented pituitary PRL secretion that was accompanied by a pattern of increased fluctuation (Table I and Fig. 1 ). This action of estrogen is prompt, with serum PRL concentrations more than doubling in 1 wk and reaching a peak by the 3rd wk to levels of more than 3 times the initial concentrations (Fig. 2) 
